Immuneering Corporation (IMRX)

NGM – Real vaqt narxi. Valyuta: USD

5.07

+0.27 (5.63%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

5.07

0.00 (0.00%)

Bozordan keyin: Aug 12, 2026, 4:01 PM EDT

05.08.2026

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

- 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported in oral presentation at ASCO Annual Meeting on June 1 - - Phase 3 MAPKeeper 301 trial is underway, with patients being dosed and over 30 study locations posted to date - - Peer-reviewed publication in Cancer Research details atebimetinib's broad, durable preclinical activity, and favorable tolerability across RAS- and RAF-mutant tumors, along with preservation of body mass - - Ended Q2 2026 with $182.7 million in cash, cash equivalents and marketable securities with anticipated runway into 2029 - NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported financial results for the second quarter ended June 30, 2026, and provided business updates. “At a time when first-line pancreatic cancer patients finally have treatment options, the 17.3 month median overall survival reported at ASCO for atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in our single-arm Phase 2a study stands out as potentially best-in-class.

Videolar

No Data

There is no data to display

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
IMRX	H.C. Wainwright	Buy	undefined >> $14	August 6th 2026

Press-relizlar

05.08.2026

Immuneering Corporation (IMRX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Immuneering Corporation (IMRX)

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

Search stocks

Immuneering Corporation (IMRX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Immuneering Corporation (IMRX)

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates